

Financial news for IMUC dated on 2019-10-23: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IMUC dated on 2018-10-17: ImmunoCellular Shares Resume Trade

Financial news for IMUC dated on 2018-10-17: ImmunoCellular Announces Receipt Of Notice Of Noncompliance With The NYSE American Continued Listing Standards; Trading Of Shares Has Been Suspended And Exchange Plans To Commence Delisting Proceedings

Financial news for IMUC dated on 2018-10-16: NYSE To Suspend Trading Of ImmunoCellular Therapeutics Shares Immediately And Commence Delisting Proceedings

Financial news for IMUC dated on 2018-10-16: ImmunoCellular Therapeutics Shares Halted, News Pending

Financial news for IMUC dated on 2018-10-16: The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

Financial news for IMUC dated on 2018-10-16: ImmunoCellular Therapeutics shares are trading lower after the company announced it would delist the stock.

Financial news for IMUC dated on 2018-10-15: ImmunoCellular Therapeutics Announces Delisting And Deregistration Of Common Stock And Listed Common Stock Warrants

Financial news for IMUC dated on 2018-08-13: ImmunoCellular Q2 EPS \$(0.01) Up From \$(1.14) YoY

Financial news for IMUC dated on 2018-07-19: ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit, Will Pay \$1.15M Fully Funded Through An Insurance Carrier For Dismissal Of All Claims Against The Co. And Its Officers And Directors

Financial news for IMUC dated on 2018-05-14: ImmunoCellular Q1 EPS \$(0.02) Up From \$(1.64) YoY

Financial news for IMUC dated on 2018-04-12: Penny Stock ImmunoCellular Therapeutics Shares Up 20.3% After Co. Reported Milestone In Stem-to-T-Cell Immuno-Oncology Program

Financial news for IMUC dated on 2018-04-12: ImmunoCellular Reports Successful Transfer Of Selected T-Cell Receptor Stem-To-T-Cell Approach, A Key Next Step To Begin Preclinical Testing

Financial news for IMUC dated on 2018-03-26: ImmunoCellular Announces Receipt of a Going Concern From its Public Accountant in its Previously Filed 10-K

Financial news for IMUC dated on 2018-03-13: ImmunoCellular Therapeutics Shares Up 5% After Hours As Co. Reported Q4 EPS Up YoY

Financial news for IMUC dated on 2018-03-13: ImmunoCellular Therapeutics Reports Q4 EPS \$(0.01) vs \$(1.36) In Same Qtr. Last Year

Financial news for IMUC dated on 2018-02-22: ImmunoCellular Therapeutics Reports Will Review Strategic Alternatives

Financial news for IMUC dated on 2018-02-13: Immunocellular Reports During Q4 Received ~\$5.77M Gross Proceeds from Exercise of Warrants Regarding July 2017 Underwritten Public Offering ; Ended 2017 With ~\$6.6M in Cash

Financial news for IMUC dated on 2017-12-14: ImmunoCellular Therapeutics +162% Premarket @\$0.58; Announced Wed Successfully Packaged T Cell Receptor DNA Sequence Into Lentiviral Vector

Financial news for IMUC dated on 2017-12-13: ImmunoCellular Therapeutics Achieves Stem-to-T-Cell Research Milestone, Successfully Packaging a T Cell Receptor DNA Sequence Into A A Lentiviral Vector

Financial news for IMUC dated on 2017-11-21: ImmunoCellular Therapeutics Reports Q3 EPS \$(0.40) vs. \$(1.58) In Same Qtr. Last Year, No Sales

Financial news for IMUC dated on 2017-09-13: ImmunoCellular Therapeutics Announces NYSE Has Accepted Co.'s Plan Of Compliance With Listing Standards

Financial news for IMUC dated on 2017-08-23: UPDATE: ImmunoCellular Says 'Near-Term Milestones Anticipated in Stem-to-T-Cell Research Program'

Financial news for IMUC dated on 2017-08-23: UPDATE: ImmunoCellular Highlights 'Restructuring Underway Designed to Achieve Cost Savings and Extend Operating Runway'

Financial news for IMUC dated on 2017-08-23: ImmunoCellular Therapeutics Offers Update On R&D Programs

Financial news for IMUC dated on 2017-08-14: ImmunoCellular Therapeutics Reports Q2 EPS \$(1.02) vs \$(2.30) In Same Qtr. Last Year

Financial news for IMUC dated on 2017-07-18: ImmunoCellular Therapeutics Prices Convertible Preferred Stock and Warrants

Financial news for IMUC dated on 2017-07-07: 15 Biggest Mid-Day Losers For Friday

Financial news for IMUC dated on 2017-07-05: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for IMUC dated on 2017-07-05: ImmunoCellular Therapeutics Shares Resume Trade, Spike Sharply Higher, Now Up 93%

Financial news for IMUC dated on 2017-06-29: ImmunoCellular Therapeutics Receives Delisting Notice From NYSE

Financial news for IMUC dated on 2017-06-21: Adam Feuerstein Tweets: The \$IMUC lesson: Trying a do-over phase 3 based on a post-hoc data nugget mined from a previous failed study not a great idea.

Financial news for IMUC dated on 2017-06-21: ImmunoCellular Therapeutics Suspends ICT-107 Phase 3 Trial Due to Financial Resources

Financial news for IMUC dated on 2017-06-05: ImmunoCellular Says Survival Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma 'Encouraging'

Financial news for IMUC dated on 2017-05-16: 18 Biggest Mid-Day Losers For Tuesday

Financial news for IMUC dated on 2017-05-15: ImmunoCellular Therapeutics Reports Q1 EPS \$(1.64) vs \$(2.47) In Same Qtr. Last Year

Financial news for IMUC dated on 2017-04-20: 8-K from Immunocellular Therapeutics Shows David Fractor Named CFO

Financial news for IMUC dated on 2017-04-04: Immunocellular Therapeutics Files to Sell Up to 10,000 Units of Preferred Stock and Warrants

Financial news for IMUC dated on 2017-03-24: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for IMUC dated on 2017-03-14: ImmunoCellular Therapeutics Gets Audit Opinion With Going Concern Explanation

Financial news for IMUC dated on 2017-03-09: ImmunoCellular Therapeutics Reports FY16 EPS \$(7.89) vs. \$(7.20) Est.

Financial news for IMUC dated on 2017-03-06: ImmunoCellular Therapeutics Gives ICT-107 Phase 3 Trial Update

Financial news for IMUC dated on 2017-02-14: Immunocellular Therapeutics Spikes to High of \$3.25 on Volume

Financial news for IMUC dated on 2017-01-11: 15 Biggest Mid-Day Losers For Wednesday

Financial news for IMUC dated on 2016-12-28: 10 Biggest Mid-Day Losers For Wednesday

Financial news for IMUC dated on 2016-12-28: ImmunoCellular Therapeutics Files For Offering Of \$20M Common Units

Financial news for IMUC dated on 2016-12-07: Immunocellular Spikes to High of \$3.17 on Volume

Financial news for IMUC dated on 2016-11-21: ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial

Financial news for IMUC dated on 2016-11-16: ImmunoCellular Announces 1:40 Reverse Split

Financial news for IMUC dated on 2016-11-11: Maxim Group Downgrades ImmunoCellular Therapeutics, Ltd. Common Stock to Hold

Financial news for IMUC dated on 2016-11-10: ImmunoCellular Reports Q3 EPS \$(0.04) vs. Est. \$(0.04)

Financial news for IMUC dated on 2016-08-22: ImmunoCellular Reports Q2 EPS \$(0.06) vs. Est. \$(0.07)

Financial news for IMUC dated on 2016-08-22: Earnings Scheduled For August 22, 2016

Financial news for IMUC dated on 2016-08-16: ImmunoCellular Therapeutics Files Non-Timely 10Q; Expects to Report Net Loss of \$5.3M for Three Months Ended June 30, 2016 vs \$3.2M for Three Months Ended June 30, 2015

Financial news for IMUC dated on 2016-08-09: There Have Been 20 Secondary Offerings Over The Last 2 Days

Financial news for IMUC dated on 2016-08-09: ImmunoCellular Therapeutics Prices 47M Shares At \$0.16/Share

Financial news for IMUC dated on 2016-07-25: ImmunoCellular Gives Update On Immunotherapy Programs

Financial news for IMUC dated on 2016-06-07: ImmunoCellular Therapeutics Reports Treating of First Patient in ICT-107 Phase 3 Registrational Trial

Financial news for IMUC dated on 2016-05-12: ImunoCellular Reports Q1 EPS \$(0.06) vs \$(0.07) Est., Sales \$4.738M

Financial news for IMUC dated on 2016-05-06: ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial

Financial news for IMUC dated on 2016-03-30: ImmunoCellular Therapeutics Reports FY15 EPS \$(0.15) vs. Prior Year \$(0.16)

Financial news for IMUC dated on 2016-03-03: Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics

Financial news for IMUC dated on 2015-12-30: Immunocellular Therapeutics Files \$50M Mixed Shelf Offering

Financial news for IMUC dated on 2015-12-14: Immunocellular Announces Agreement with Canadian brain Tumour For Trail

Financial news for IMUC dated on 2015-12-07: ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials for ICT-107 Phase 3 Registrational Trial in Glioblastoma; ALso Awarded \$19.9M From California

Financial news for IMUC dated on 2015-12-01: ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma

Financial news for IMUC dated on 2015-11-20: ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015

Financial news for IMUC dated on 2015-09-24: Roth Capital Reiterates Buy on ImmunoCellular Following News of Grant from CIRM, Says 'Major Overhang Removed as CIRM Steps Up in a Big Way'

Financial news for IMUC dated on 2015-09-24: Shares of ImmunoCellular Resumed Trade Up ~16%

Financial news for IMUC dated on 2015-09-24: UPDATE: ImmunoCellular Says On Track to Begin Phase 3 ICT-107 Trial in Q4'15

Financial news for IMUC dated on 2015-09-24: ImmunoCellular Therapeutics Announces Winning of \$19.9M Grant from CIRM to Fund ICT-107 Phase 3 Trial

Financial news for IMUC dated on 2015-09-24: UPDATE: CIRM @CIRMnews Tweet: CIRM Board just approves \$19.9m for .@Immunocellular Phase 3 clinical trial for glioblastoma

Financial news for IMUC dated on 2015-09-24: CIRM Board just approves \$19.9m for .@Immunocellular Phase 3 Clinical Trial for Glioblastoma

Financial news for IMUC dated on 2015-09-24: ImmunoCellular Therapeutics Halted; Pending News

Financial news for IMUC dated on 2015-08-21: ImmunoCellular Announces Update on ICT-107

Financial news for IMUC dated on 2015-08-21: ImmunoCellular Therapeutics Letter to Shareholders Highlights Progress on Advancing ICT-107 to Phase 3 Registrational Trial

Financial news for IMUC dated on 2015-08-13: Morning Market Gainers

Financial news for IMUC dated on 2015-08-13: ImmunoCellular Therapeutics +50% Premarket as Co Announces Agreement with FDA on Special Protocol Assessment for ICT-107 Phase 3 Registrational Trial in Glioblastoma

Financial news for IMUC dated on 2015-08-06: ImmunoCellular Therapeutics Reports Q2 EPS \$(0.03) vs. Est. \$(0.05)

Financial news for IMUC dated on 2015-06-22: ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial

Financial news for IMUC dated on 2015-06-15: ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial

Financial news for IMUC dated on 2015-03-19: ImmunoCellular to Initiate Phase 3 Registrational Program for ICT-107 in US, Europe in 2015

Financial news for IMUC dated on 2015-03-09: ImmunoCellular Therapeutics Reports Q4 EPS -\$0.03 Vs Est -\$0.05

Financial news for IMUC dated on 2015-02-12: ImmunoCellular Therapeutics Prices 26.7M Share Offering

Financial news for IMUC dated on 2015-02-10: ImmunoCellular Therapeutics Announces 18.3M Share Offering, Warrants to Purchase 12.8M Shares

Financial news for IMUC dated on 2014-12-17: ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine

Financial news for IMUC dated on 2014-12-12: S-1 Filing For Immunocellular Therapeutics Shows Offering Of Up To \$20M Shares

Financial news for IMUC dated on 2014-12-01: US Stock Futures Down; Crude Oil Tumbles Over 1%

Financial news for IMUC dated on 2014-12-01: ImmunoCellular Therapeutics Reports Positive Regulatory Feedback from EMA on Advancing ICT-107 to Phase III Program

Financial news for IMUC dated on 2014-11-14: Immunocellular Therapeutics Presents Promising ICT-107 Phase II Data at Society For Neuro-Oncology Annual Meeting 2014

Financial news for IMUC dated on 2014-09-24: US Stock Futures Up Ahead Of New Home Sales Report

Financial news for IMUC dated on 2014-09-24: ImmunoCellular Therapeutics in Licensing Deal with Caltech for Antigen Specific T-cell Immunotherapies for Treatment of Cancer

Financial news for IMUC dated on 2014-09-17: ImmunoCellular Therapeutics Announces Positive Regulatory Feedback on ICT-107

Financial news for IMUC dated on 2014-08-22: Immunocellular Therapeutics VP Gringeri Buys 11,000 Shares @\$0.91/Share -Form 4

Financial news for IMUC dated on 2014-08-19: 5 Companies Developing New Cancer Drugs

Financial news for IMUC dated on 2014-08-07: ImmunoCellular Therapeutics, Ltd. Reports Q2 EPS of \$(0.04) vs \$(0.06) Est

Financial news for IMUC dated on 2014-06-01: ImmunoCellular Therapeutics Presents Positive ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at ASCO

Financial news for IMUC dated on 2014-05-08: ImmunoCellular Therapeutics, Ltd. Reports Q1 EPS of \$(0.05) vs \$(0.04) Est

Financial news for IMUC dated on 2014-03-20: roberto pedone Tweet: \$IMUC bio chart with great setup here. Could be primed for a big % move-
[stockcharts.com/h-sc/ui?s=IMUC...](http://stockcharts.com/h-sc/ui?s=IMUC)

Financial news for IMUC dated on 2014-03-13: ImmunoCellular Therapeutics, Ltd. Reports Q4 EPS of \$0.00 vs \$(0.09) Est

Financial news for IMUC dated on 2014-02-25: Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

Financial news for IMUC dated on 2014-01-22: Morning Market Losers

Financial news for IMUC dated on 2014-01-21: Morning Market Movers

Financial news for IMUC dated on 2014-01-09: UPDATE: ImmunoCellular Shares Now Up 22% After-Hours on Shareholder Letter Providing Update on ICT-107

Financial news for IMUC dated on 2014-01-09: Immunocellular Therapeutics Says Did Not Meet OS Endpoint in ICT-107 Program, Says PFS Endpoint Was Met

Financial news for IMUC dated on 2013-12-23: UPDATE: Immunocellular Says Seeking Meeting with FDA Related to Phase II Trial of ICT-107, Expecting to Have Three Active Cancer Vaccine Programs in 2014

Financial news for IMUC dated on 2013-12-23: UPDATE: Immunocellular Says Seeking Meeting with FDA Related to Phase II Trial of ICT-107, Expecting to Have Three Active Cancer Vaccine Programs in 2014

Financial news for IMUC dated on 2013-12-23: ImmunoCellular Reports First Patient Has Received Vaccine in Phase I Trial of ICT-121

Financial news for IMUC dated on 2013-12-12: Morning Market Losers

Financial news for IMUC dated on 2013-12-12: UPDATE: MLV & Co. Downgrades ImmunoCellular Therapeutics on Negative Outlook for ICT-107

Financial news for IMUC dated on 2013-12-12: Roth Capital Downgrades ImmunoCellular Therapeutics, Ltd. to Neutral

Financial news for IMUC dated on 2013-12-12: McNicoll Lewis Vlak Downgrades ImmunoCellular Therapeutics, Ltd. to Hold, Lowers PT to \$1.25

Financial news for IMUC dated on 2013-12-11: ImmunoCellular Therapeutics Announces Positive ICT-107 Phase II Study Results

Financial news for IMUC dated on 2013-12-03: US Stock Futures Signal Lower Start On Wall Street

Financial news for IMUC dated on 2013-12-03: ImmunoCellular Therapeutics Expands Manufacturing Relationship with Neostem's Progenitor Cell Therapy

Financial news for IMUC dated on 2013-11-06: ImmunoCellular Therapeutics, Ltd. Reports Q3 EPS of \$(0.07) vs \$(0.06) Est

Financial news for IMUC dated on 2013-08-29: Benzinga's Top Initiations

Financial news for IMUC dated on 2013-08-28: ImmunoCellular Therapeutics Appoints Anthony J. Gringeri, PhD, as Senior Vice President, Strategic Resources

Financial news for IMUC dated on 2013-08-07: ImmunoCellular Therapeutics, Ltd. Reports Q2 EPS of \$0.00 vs \$(0.08) Est; Revenue of \$0.00

Financial news for IMUC dated on 2013-08-06: Immunocellular Shares Moving Higher; May be Attributed to Seeking Alpha Post

Financial news for IMUC dated on 2013-06-07: ImmunoCellular Announces Data Monitoring Committee Recommends Continuation of ICT-107 Phase II Trial

Financial news for IMUC dated on 2013-06-03: NeoStem's PCT Announces Manufacturing Deal with Immunocellular for Dendritic Cell Vaccines

Financial news for IMUC dated on 2013-05-09: ImmunoCellular Therapeutics, Ltd. Reports Q1 EPS of \$(0.10) vs \$(0.08) Est

Financial news for IMUC dated on 2013-03-06: McNicoll Lewis Vlak Maintains Buy on ImmunoCellular Therapeutics, Ltd., Raises PT to \$5.00

Financial news for IMUC dated on 2013-03-05: ImmunoCellular Therapeutics, Ltd. Reports Q4 EPS of \$0.01 vs \$(0.08) Est

Financial news for IMUC dated on 2012-12-03: Immunocellular Therapeutics Names Andrew Gengos CEO

Financial news for IMUC dated on 2012-10-18: ImmunoCellular Therapeutics Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants

Financial news for IMUC dated on 2012-10-17: ImmunoCellular Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Financial news for IMUC dated on 2012-08-21: Benzinga's Top Pre-Market Losers

Financial news for IMUC dated on 2012-08-21: US Stock Futures Up; Euro Rises Against Dollar

Financial news for IMUC dated on 2012-08-21: Stocks To Watch For August 21, 2012

Financial news for IMUC dated on 2012-08-20: ImmunoCellular Says CEO Manish Resigned; Yu Named Interim CEO

Financial news for IMUC dated on 2012-08-08: A Peek Into The Market Before The Trading Starts

Financial news for IMUC dated on 2012-08-08: ImmunoCellular Therapeutics' Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy

Financial news for IMUC dated on 2012-07-25: ImmunoCellular Therapeutics Announces Clearance of IND Application for Phase I Study of Company's Second Vaccine Product Candidate in Recurrent GBM

Financial news for IMUC dated on 2012-07-02: ImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of Glioblastoma

Financial news for IMUC dated on 2012-05-31: ImmunoCellular Therapeutics Says Data on ICT-107 Shows 50% Survival After 4 Years

Financial news for IMUC dated on 2012-05-25: MLV & Co Reiterates Buy, \$4.50 PT on ImmunoCellular Therapeutics on Move to NYSE

Financial news for IMUC dated on 2012-04-24: Multiple Antigen Targeting Could Mean Multiple Marketing for These Immunotherapy Drugs

Financial news for IMUC dated on 2012-04-21: Stem Cell Biotechs: A Frontrunner Emerges?

Financial news for IMUC dated on 2012-01-23: ImmunoCellular Therapeutics Provides Update on Phase II Clinical Trial of ICT-107 for the Treatment of Glioblastoma

Financial news for IMUC dated on 2011-10-03: NeoStem's Subsidiary, Progenitor Cell Therapy, and ImmunoCellular Therapeutics Enter Into a Manufacturing Agreement

Financial news for IMUC dated on 2011-01-14: ImmunoCellular Therapeutics (IMUC): Update from Healthcare conference in San Francisco - Analyst Blog

Financial news for IMUC dated on 2011-01-14: ImmunoCellular Therapeutics (IMUC): Update from Healthcare conference in San Francisco - Analyst Blog

Financial news for IMUC dated on 2010-12-20: ImmunoCellular Therapeutics (IMUC): At the Forefront of Brain Tumor Treatment - Analyst Blog

Financial news for IMUC dated on 2010-12-01: ImmunoCellular Therapeutics (IMUC) : At the Forefront of Targeting Cancer Stem Cells (II) - Analyst Blog